Bioelectric pro
Galvani Bioelectronics, the developer of bioelectronic medicines launched by GlaxoSmithKline and Alphabets life science play Verily (formerly Google Life Sciences) in early August, will have a bioelectronic visionary on board. Moncef Slaoui, who expedited GSK investments in the field of bioelectronics, will be the chairman of the new companys Board of Directors.
Slaoui currently serves as GSKs Chairman of Global Vaccines and previously was Chairman of GSK R&D. He holds a PhD in Molecular Biology and Immunology from Brussels University and was a professor of Immunology at the Belgian University of Mons. He is a member of the PhRMA Foundation Board of Directors, National Institutes of Health Advisory Committee to the Director, and the Biotechnology Industry Organization Board of Directors.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium